2.1 Million Women: Breast Cancer Treatment Developed By This Company

Plus Therapeutics Gains FDA Orphan Drug Designation for Groundbreaking Breast Cancer Treatment.

In a significant stride forward for the medical community and patients alike, Plus Therapeutics, a clinical-stage pharmaceutical company, has recently received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). The designation is for their innovative Bmeda-chelated Rhenium-186 Nanoliposomes, which are being developed for the treat…